Neurofibromatosis type 1 revisited

Area of Science:

• Genetics and Molecular Biology
• Clinical Medicine
• Oncology

Background:

• Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with a global incidence of 1 in 2500–3000.
• It stems from germ-line-inactivating mutations in the NF1 gene on chromosome 17, leading to significant morbidity and mortality.
• NF1 protein (neurofibromin) dysfunction in cell growth regulation underlies the disease's pathogenesis.

Purpose of the Study:

• To review the current understanding of Neurofibromatosis type 1.
• To detail clinical manifestations, recent genetic and molecular findings, and therapeutic strategies.
• To provide an overview of standardized management and emerging treatments for NF1.

Main Methods:

• Literature review of clinical studies and genetic research on NF1.
• Analysis of recent advancements in understanding neurofibromin's role in cell growth.
• Synthesis of information on current and developing therapeutic approaches.

Main Results:

• Significant progress has been achieved in standardizing the management of major NF1 clinical features.
• New insights into neurofibromin's function have illuminated NF1 pathogenesis.
• Development of novel therapeutic strategies for NF1 is underway.

Conclusions:

• NF1 management has seen substantial improvements through standardized approaches.
• Understanding neurofibromin's molecular function is key to developing targeted therapies for NF1.
• This review consolidates current knowledge and future directions for NF1 care.